• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Jennifer S. Temel, MD


  • Cox JV, Ward JC, Hornberger JC, Temel JS, McAneny BL.Community oncology in an era of payment reform.Am Soc Clin Oncol Educ Book. 2014;34:e447-52.
  • Shin JA, Kosiba JD, Traeger L, Greer JA, Temel JS, Pirl WF.Dyspnea and Panic Among Patients With Newly Diagnosed Non-Small-Cell Lung Cancer.J Pain Symptom Manage. 2014 Apr 21.
  • Greer JA, Pirl WF, Jackson VA, Muzikansky A, Lennes IT, Gallagher ER, Prigerson HG, Temel JS.Perceptions of Health Status and Survival in¬†Patients With Metastatic Lung Cancer.J Pain Symptom Manage. 2014 Mar 27.
  • Greer JA, Lennes IT, Gallagher ER, Temel JS, Pirl WF.Documentation of oral versus intravenous chemotherapy plans in patients with metastatic non-small-cell lung cancer.J Oncol Pract. 2014 Mar 1;10(2):e103-6.
  • Parikh RB, Temel JS.Early specialty palliative care.N Engl J Med. 2014 Mar 13;370(11):1075-6.
  • Fletcher K, Prigerson HG, Paulk E, Temel J, Finlay E, Marr L, McCorkle R, Rivera L, Munoz F, Maciejewski PK.Gender differences in the evolution of illness understanding among patients with advanced cancer.J Support Oncol. 2013 Sep;11(3):126-32.
  • El-Jawahri A, Traeger L, Park ER, Greer JA, Pirl WF, Lennes IT, Jackson VA, Gallagher ER, Temel JS.Associations among prognostic understanding, quality of life, and mood in patients with advanced cancer.Cancer. 2014 Jan 15;120(2):278-85.
  • Parikh RB, Kirch RA, Smith TJ, Temel JS.Early specialty palliative care--translating data in oncology into practice.N Engl J Med. 2013 Dec 12;369(24):2347-51.
  • Shih YC, Ganz PA, Aberle D, Abernethy A, Bekelman J, Brawley O, Goodwin JS, Hu JC, Schrag D, Temel JS, Schnipper L.Delivering high-quality and affordable care throughout the cancer care continuum.J Clin Oncol. 2013 Nov 10;31(32):4151-7.
  • Krishnan MS, Epstein-Peterson Z, Chen YH, Tseng YD, Wright AA, Temel JS, Catalano P, Balboni TA.Predicting life expectancy in patients with metastatic cancer receiving palliative radiotherapy: The TEACHH model.Cancer. 2013 Oct 2.
  • Kumar P, Temel JS.End-of-life care discussions in patients with advanced cancer.J Clin Oncol. 2013 Sep 20;31(27):3315-9.
  • Greer JA, Jackson VA, Meier DE, Temel JS.Early integration of palliative care services with standard oncology care for patients with advanced cancer.CA Cancer J Clin. 2013 Sep;63(5):349-63. Review.
  • Krishnan M, Temel JS, Wright AA, Bernacki R, Selvaggi K, Balboni T.Predicting life expectancy in patients with advanced incurable cancer: a review.J Support Oncol. 2013 Jun;11(2):68-74. Review.
  • Jackson VA, Jacobsen J, Greer JA, Pirl WF, Temel JS, Back AL.The cultivation of prognostic awareness through the provision of early palliative care in the ambulatory setting: a communication guide.J Palliat Med. 2013 Aug;16(8):894-900.
  • Shin J, Temel J.Integrating palliative care: when and how?.Curr Opin Pulm Med. 2013 Jul;19(4):344-9.
  • Smith AK, Thai JN, Bakitas MA, Meier DE, Spragens LH, Temel JS, Weissman DE, Rabow MW.The Diverse Landscape of Palliative Care Clinics.J Palliat Med. 2013 May 10.
  • Yoong J, Traeger LN, Gallagher ER, Pirl WF, Greer JA, Temel JS.A Pilot Study To Investigate Adherence to Long-Acting Opioids among Patients with Advanced Lung Cancer.J Palliat Med. 2013 Apr;16(4):391-6.
  • Roeland E, Loprinzi C, Moynihan TJ, Smith TJ, Temel J.In chemotherapy for lung cancer, sometimes less is more.J Natl Compr Canc Netw. 2013 Mar 1;11(3):232-5.
  • Yoong J, Park ER, Greer JA, Jackson VA, Gallagher ER, Pirl WF, Back AL, Temel JS.Early palliative care in advanced lung cancer: a qualitative study.JAMA Intern Med. 2013 Feb 25;173(4):283-90.
  • Temel JS, Greer JA, Gallagher ER, Jackson VA, Lennes IT, Muzikansky A, Park ER, Pirl WF.Electronic prompt to improve outpatient code status documentation for patients with advanced lung cancer.J Clin Oncol. 2013 Feb 20;31(6):710-5.
  • Pirl WF, Traeger L, Greer JA, Jackson V, Lennes IT, Gallagher E, Sequist L, Temel JS.Depression, survival, and epidermal growth factor receptor genotypes in patients with metastatic non-small cell lung cancer.Palliative & Supportive Care. 2013 Feb 11:1-7.
  • Irwin KE, Greer JA, Khatib J, Temel JS, Pirl WF.Early palliative care and metastatic non-small cell lung cancer: potential mechanisms of prolonged survival.Chron Respir Dis. 2013 Feb;10(1):35-47.
  • Lennes IT, Temel JS, Hoedt C, Meilleur A, Lamont EB.Predictors of newly diagnosed cancer patients' understanding of the goals of their care at initiation of chemotherapy.Cancer. 2013 Feb 1;119(3):691-9.
  • Volandes AE, Paasche-Orlow MK, Mitchell SL, El-Jawahri A, Davis AD, Barry MJ, Hartshorn KL, Jackson VA, Gillick MR, Walker-Corkery ES, Chang Y, L√≥pez L, Kemeny M, Bulone L, Mann E, Misra S, Peachey M, Abbo ED, Eichler AF, Epstein AS, Noy A, Levin TT, Temel JS.Randomized controlled trial of a video decision support tool for cardiopulmonary resuscitation decision making in advanced cancer.J Clin Oncol. 2013 Jan 20;31(3):380-6.
  • Kamal AH, Swetz KM, Dy S, Tien AY, Temel JS, Abernethy AP.Integrating technology into palliative care research.Curr Opin Support Palliat Care. 2012 Dec;6(4):525-32. Review.
  • Greer JA, Traeger L, Bemis H, Solis J, Hendriksen ES, Park ER, Pirl WF, Temel JS, Prigerson HG, Safren SA.A pilot randomized controlled trial of brief cognitive-behavioral therapy for anxiety in patients with terminal cancer.Oncologist. 2012;17(10):1337-45.
  • McCannon JB, O'Donnell WJ, Thompson BT, El-Jawahri A, Chang Y, Ananian L, Bajwa EK, Currier PF, Parikh M, Temel JS, Cooper Z, Wiener RS, Volandes A.Augmenting Communication and Decision Making in the Intensive Care Unit with a Cardiopulmonary Resuscitation Video Decision Support Tool: A Temporal Intervention Study.J Palliat Med. 2012 Oct 25.
  • Levy MH, Adolph MD, Back A, Block S, Codada SN, Dalal S, Deshields TL, Dexter E, Dy SM, Knight SJ, Misra S, Ritchie CS, Sauer TM, Smith T, Spiegel D, Sutton L, Taylor RM, Temel J, Thomas J, Tickoo R, Urba SG, Von Roenn JH, Weems JL, Weinstein SM, Freedman-Cass DA, Bergman MA, .Palliative care.J Natl Compr Canc Netw. 2012 Oct 1;10(10):1284-309.
  • Goldberg SB, Supko JG, Neal JW, Muzikansky A, Digumarthy S, Fidias P, Temel JS, Heist RS, Shaw AT, McCarthy PO, Lynch TJ, Sharma S, Settleman JE, Sequist LV.A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.J Thorac Oncol. 2012 Oct;7(10):1602-8.
  • Pirl WF, Greer JA, Traeger L, Jackson V, Lennes IT, Gallagher ER, Perez-Cruz P, Heist RS, Temel JS.Depression and Survival in Metastatic Non-Small-Cell Lung Cancer: Effects of Early Palliative Care.J Clin Oncol. 2012 Mar 19.
  • Traeger L, Greer JA, Fernandez-Robles C, Temel JS, Pirl WF.Evidence-Based Treatment of Anxiety in Patients With Cancer.J Clin Oncol. 2012 Mar 12.
  • Greer JA, Pirl WF, Jackson VA, Muzikansky A, Lennes IT, Heist RS, Gallagher ER, Temel JS.Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer.J Clin Oncol. 2012 Feb 1;30(4):394-400.
  • Von Roenn JH, Temel J.The integration of palliative care and oncology: the evidence.Oncology (Huntingt). 2011 Nov 30;25(13):1258-60, 1262, 1264-5.
  • McCannon J, Temel J.Comprehensive management of respiratory symptoms in patients with advanced lung cancer.J Support Oncol.;10(1):1-9. Review.
  • Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, Janne PA, Ko AH, Masters GA, Odenike O, Patel JD, Roth BJ, Samlowski WE, Seidman AD, Tap WD, Temel JS, Von Roenn JH, Kris MG.Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.J Clin Oncol. 2012 Jan 1;30(1):88-109.
  • Pirl WF, Traeger L, Greer JA, Bemis H, Gallagher E, Lennes I, Sequist L, Heist R, Temel JS.Tumor Epidermal Growth Factor Receptor Genotype and Depression in Stage IV Non-Small Cell Lung Cancer.Oncologist. 2011;16(9):1299-306.
  • Greer JA, Solis JM, Temel JS, Lennes IT, Prigerson HG, Maciejewski PK, Pirl WF.Anxiety disorders in long-term survivors of adult cancers.Psychosomatics.;52(5):417-23.
  • El-Jawahri A, Greer JA, Temel JS.Does palliative care improve outcomes for patients with incurable illness? A review of the evidence.J Support Oncol.;9(3):87-94. Review.
  • Temel JS, Greer JA, Admane S, Gallagher ER, Jackson VA, Lynch TJ, Lennes IT, Dahlin CM, Pirl WF.Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care.J Clin Oncol. 2011 Jun 10;29(17):2319-26.
  • Park ER, Japuntich S, Temel J, Lanuti M, Pandiscio J, Hilgenberg J, Davies D, Dresler C, Rigotti NA.A Smoking Cessation Intervention for Thoracic Surgery and Oncology Clinics: A Pilot Trial.J Thorac Oncol. 2011 Apr 20.
  • Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA.Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors.Sci Transl Med. 2011 Mar 23;3(75):75ra26.
  • Jacobsen J, Jackson V, Dahlin C, Greer J, Perez-Cruz P, Billings JA, Pirl W, Temel J.Components of Early Outpatient Palliative Care Consultation in Patients with Metastatic Nonsmall Cell Lung Cancer.J Palliat Med. 2011 Mar 18.
  • Traeger L, Braun IM, Greer JA, Temel JS, Cashavelly B, Pirl WF.Parsing Depression From Fatigue in Patients with Cancer Using the Fatigue Symptom Inventory.J Pain Symptom Manage. 2011 Mar 11.
  • Krug LM, Crawford J, Ettinger DS, Shapiro GI, Spigel D, Reiman T, Temel JS, Michelson GC, Young DY, Hoch U, Adelman DC.Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer.J Thorac Oncol. 2011 Feb;6(2):384-6.
  • Chan JA, Blaszkowsky LS, Enzinger PC, Ryan DP, Abrams TA, Zhu AX, Temel JS, Schrag D, Bhargava P, Meyerhardt JA, Wolpin BM, Fidias P, Zheng H, Florio S, Regan E, Fuchs CS.A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma.Ann Oncol. 2011 Jan 7.
  • Neal JW, Heist RS, Fidias P, Temel JS, Huberman M, Marcoux JP, Muzikansky A, Lynch TJ, Sequist LV.Cetuximab Monotherapy in Patients with Advanced Non-small Cell Lung Cancer After Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy.J Thorac Oncol. 2010 Nov;5(11):1855-8.
  • Dahlin CM, Kelley JM, Jackson VA, Temel JS.Early palliative care for lung cancer: improving quality of life and increasing survival.Int J Palliat Nurs. 2010 Sep;16(9):420-3.
  • Heist RS, Fain J, Chinnasami B, Khan W, Molina JR, Sequist LV, Temel JS, Fidias P, Brainerd V, Leopold L, Lynch TJ.Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer.J Thorac Oncol. 2010 Oct;5(10):1637-43.
  • Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ.Early palliative care for patients with metastatic non-small-cell lung cancer.N Engl J Med. 2010 Aug 19;363(8):733-42.
  • Temel JS, Greer JA, Admane S, Solis J, Cashavelly BJ, Doherty S, Heist R, Pirl WF.Code status documentation in the outpatient electronic medical records of patients with metastatic cancer.J Gen Intern Med. 2010 Feb;25(2):150-3.
  • El-Jawahri A, Podgurski LM, Eichler AF, Plotkin SR, Temel JS, Mitchell SL, Chang Y, Barry MJ, Volandes AE.Use of video to facilitate end-of-life discussions with patients with cancer: a randomized controlled trial.J Clin Oncol. 2010 Jan 10;28(2):305-10.
  • Loggers ET, Maciejewski PK, Paulk E, Desanto-Madeya S, Nilsson M, Viswanath K, Wright AA, Balboni TA, Temel J, Stieglitz H, Block S, Prigerson HG.Racial Differences in Predictors of Intensive End-of-Life Care in Advanced Cancer Patients.J Clin Oncol. 2009 Nov 20;27(33):5559-64.
  • Sequist LV, Fidias PM, Temel JS, Kolevska T, Rabin MS, Boccia RV, Burris HA, Belt RJ, Huberman MS, Melnyk O, Mills GM, Englund CW, Caldwell DC, Keck JG, Meng L, Jones M, Brown GL, Edelman MJ, Lynch TJ.Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer.J Thorac Oncol. 2009 Nov;4(11):1389-96.
  • Pirl WF, Greer J, Temel JS, Yeap BY, Gilman SE.Major Depressive Disorder in Long-Term Cancer Survivors: Analysis of the National Comorbidity Survey Replication.J Clin Oncol. 2009 Sep 1;27(25):4130-4.
  • Pirl WF, Solis J, Greer J, Sequist L, Temel JS, Lynch TJ.Epidermal growth factor receptor tyrosine kinase inhibitors and depression.J Clin Oncol. 2009 Aug 10;27(23):e49-50; author reply e51.
  • Muriel AC, Hwang VS, Kornblith A, Greer J, Greenberg DB, Temel J, Schapira L, Pirl W.Management of psychosocial distress by oncologists.Psychiatr Serv. 2009 Aug;60(8):1132-4.
  • Paddison JS, Temel JS, Fricchione GL, Pirl WF.Using the differential from complete blood counts as a biomarker of fatigue in advanced non-small-cell lung cancer: an exploratory analysis.Palliative & Supportive Care. 2009 Jun;7(2):213-7.
  • Temel JS,Greer JA,Goldberg S,Vogel PD,Sullivan M,Pirl WF,Lynch TJ,Christiani DC,Smith MR.A structured exercise program for patients with advanced non-small cell lung cancer.J Thorac Oncol. 2009 May;4(5):595-601.
  • Greer JA,Pirl WF,Park ER,Lynch TJ,Temel JS.Behavioral and psychological predictors of chemotherapy adherence in patients with advanced non-small cell lung cancer.J Psychosom Res. 2008 Dec;65(6):549-52.
  • Heist RS,Fidias P,Huberman M,Ardman B,Sequist LV,Temel JS,Lynch TJ.A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer.J Thorac Oncol. 2008 Oct;3(10):1153-8.
  • Temel JS,McCannon J,Greer JA,Jackson VA,Ostler P,Pirl WF,Lynch TJ,Billings JA.Aggressiveness of care in a prospective cohort of patients with advanced NSCLC.Cancer. 2008 Aug 15;113(4):826-33.
  • Pirl WF, Temel JS, Billings A, Dahlin C, Jackson V, Prigerson HG, Greer J, Lynch TJ.Depression after diagnosis of advanced non-small cell lung cancer and survival: a pilot study.Psychosomatics. 2008 May-Jun;49(3):218-24.
  • Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS, Clark JR, Lynch TJ.A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer.Thyroid. 2008 Mar;18(3):317-23.
  • Pirl WF, Muriel A, Hwang V, Kornblith A, Greer J, Donelan K, Greenberg DB, Temel J, Schapira L.Screening for psychosocial distress: a national survey of oncologists.J Support Oncol. 2007 Nov-Dec;5(10):499-504.
  • Bradbury PA, Heist RS, Kulke MH, Zhou W, Marshall AL, Miller DP, Su L, Park S, Temel J, Fidias P, Sequist L, Lynch TJ, Wain JC, Shepherd FA, Christiani DC, Liu G.A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studies.Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):204-11.
  • Temel JS, Jackson VA, Billings JA, Dahlin C, Block SD, Buss MK, Ostler P, Fidias P, Muzikansky A, Greer JA, Pirl WF, Lynch TJ.Phase II study: integrated palliative care in newly diagnosed advanced non-small-cell lung cancer patients.J Clin Oncol. 2007 Jun 10;25(17):2377-82.
  • Shi AA, Digumarthy SR, Temel JS, Halpern EF, Kuester LB, Aquino SL.Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer?.J Thorac Oncol. 2006 Mar;1(3):205-10.
  • Temel JS, Pirl WF, Recklitis CJ, Cashavelly B, Lynch TJ.Feasibility and validity of a one-item fatigue screen in a thoracic oncology clinic.J Thorac Oncol. 2006 Jun;1(5):454-9.
  • Temel J.Complexities of quality of life analysis in non-small cell lung cancer.J Support Oncol. 2007 Jan;5(1):30-1. Review.
  • Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Jšnne PA.Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.J Clin Oncol. 2007 Mar 1;25(7):760-6.
  • Temel JS, Pirl WF, Lynch TJ.Comprehensive symptom management in patients with advanced-stage non-small-cell lung cancer.Clin Lung Cancer. 2006 Jan;7(4):241-9. Review.
  • Temel J.Can weight loss at presentation predict patient outcome in lung cancer?.Nat Clin Pract Oncol. 2004 Dec;1(2):68-9.
  • P√©rez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, von Pawel J, Temel J, Siena S, Souli√®res D, Saltz L, Leyden J.HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.Oncologist. 2005 May;10(5):345-56. Review.
  • Donovan J, Temel J, Zuckerman A, Gribben J, Fang J, Pierson G, Ross A, Diller L, Grupp SA.CD34 selection as a stem cell purging strategy for neuroblastoma: preclinical and clinical studies.Med Pediatr Oncol. 2000 Dec;35(6):677-82.